MedPath

Effect of nicotine patch in Cognitive function improvement in Parkinson's disease

Not Applicable
Recruiting
Conditions
Parkinson&#39
s disease
Registration Number
JPRN-UMIN000016664
Lead Sponsor
Department of Clinical Pharmacology and Neurology Ehime University graduated School of Medicine
Brief Summary

Not available

Detailed Description

Not available

Recruitment & Eligibility

Status
Recruiting
Sex
All
Target Recruitment
20
Inclusion Criteria

Not provided

Exclusion Criteria

They received donepezil, galanthamine, administration of rivastigmine within study initiation two weeks. There was a change of the dose direction for use to an antiparkinson agent and the centrally acting drug (anxiolytics, antidepressants, anticonvulsant) taking. There is a remarkable disability in heart and the lungs liver renal function. The chief physician think the patient is inappropriate.

Study & Design

Study Type
Interventional
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
score of the driving simulator
Secondary Outcome Measures
NameTimeMethod
Distribution ratio of alpha wave Trail Making Test
© Copyright 2025. All Rights Reserved by MedPath